Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


President signs JOBS bill

This article was originally published in The Tan Sheet

Executive Summary

Multinational pharma, dietary supplement and nutritional product manufacturers will pay a reduced tax rate for repatriated foreign earnings after President Bush signed the legislation into law on Oct. 22. The bill cuts the repatriation tax rate from 35% to 5.25%, giving firms an incentive to repatriate earnings in the U.S. (1"The Tan Sheet" Oct. 18, 2004, p. 7). In an Oct. 29 earnings call, Schering-Plough CFO Bob Bertolini called the legislation "a very positive development" that will provide added financial flexibility, but noted it is "too early" to speculate how much of the firm's $9 bil. in undistributed foreign earnings will be repatriated...

You may also be interested in...

Pharma Firms Ready To Repatriate Billions Once “JOBS” Bill Is Signed

J&J intends to repatriate as much as $10 bil. held by foreign subsidiaries following President Bush's expected signing of the "JOBS" bill

FDA Commissioner Nominee Hahn Advances To Full Senate, Despite Some Dems’ Reservations

Stephen Hahn, the Trump administration’s nominee to lead the US FDA, has been approved by the Senate Health, Education, Labor and Pensions (HELP) Committee, with some “no votes” from Democratic senators in leadership positions, and is expected to be considered by the full Senate this week.

FDA Holding February Public Meeting On Using AI In Radiology

The US agency will host a two-day meeting to discuss the evolution of artificial intelligence technology used to analyze radiological images when diagnosing patients and in advising radiologists to take optimal pictures. The takeaways from the meeting will be used by the FDA to help it develop its thinking on how to regulate such technology.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts